Intetumumab
Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) [1].
Product Specifications
CAS Number
[725735-28-4]
Product Name Alternative
CNTO 95; Anti-Human CD51 Recombinant Antibody
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/intetumumab.html
Purity
99.24
Solubility
10 mM in DMSO
Smiles
[Intetumumab]
Molecular Weight
(145.14 kDa)
References & Citations
[1]Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21 (6) :1084-90.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1306039-01 0.5 mg (E-Coli)
Recombinant Arabidopsis thaliana Wall-associated receptor kinase-like 22 (WAKL22), partial
Ask
View Details MBS1306039-02 0.05 mg (Baculovirus)
Recombinant Arabidopsis thaliana Wall-associated receptor kinase-like 22 (WAKL22), partial
Ask
View Details